Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) has announced a non-brokered private placement expected to raise gross proceeds of approximately C$5 million. The financing involves the issuance of 6,764,069 units at a price of C$0.7392 per unit, with each unit consisting of one common share and one warrant. Each warrant entitles the holder to purchase one common share at an exercise price of C$0.90 per share for a period of three years from the closing date.
The private placement is expected to close on or about July 10, 2026, subject to regulatory approvals, including approval from Cboe Canada. The company plans to use the net proceeds to advance its ONC010 program through manufacturing and preclinical testing activities, support the development of its SynoGraph(TM) platform, and provide working capital for general corporate purposes.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumours.
This financing is being conducted under Canada's Listed Issuer Financing Exemption, which means that the securities issued under the financing will not be subject to a hold period under applicable Canadian securities laws. This exemption allows for a more streamlined process and quicker access to capital for growth-oriented companies like Onco-Innovations.
The announcement highlights the company's continued progress in developing its oncology pipeline. The ONC010 program is a key focus, and the funds will enable the company to move forward with manufacturing and preclinical testing, which are critical steps toward potential clinical trials. The SynoGraph(TM) platform is another important asset that could enhance the company's ability to develop targeted cancer therapies.
For investors, this private placement represents an opportunity to participate in the company's growth at a set price, with the added incentive of warrants that could provide future upside. The financing also underscores investor confidence in Onco-Innovations' strategy and technology.
More information about the company and its latest updates is available in its newsroom at NNW's ONNVF newsroom. The full press release can be accessed at https://www.nnw.fm/QatCe.
